The treatment-naive microbiome in new-onset Crohn's diseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the gut microbiome in patients with new-onset Crohn's disease before they had started any treatment. Samples were collected from multiple gastrointestinal locations, including the ileum and rectum, as well as fecal samples. The goal was to characterize microbial dysbiosis at the earliest, treatment-naive stage of disease and to compare microbial signatures across sample sites and antibiotic exposure status.
Who was studied?
The study drew on the largest pediatric Crohn's disease cohort assembled for microbiome analysis to date. Participants were newly diagnosed, treatment-naive children and adolescents with Crohn's disease. The abstract does not give an exact sample size or additional demographic detail.
What were the most important findings?
An axis of dysbiosis emerged in which Enterobacteriaceae, Pasteurellaceae, Veillonellaceae, and Fusobacteriaceae were increased, while Erysipelotrichales, Bacteroidales, and Clostridiales were decreased, and this axis correlated strongly with disease status. Comparing patients with and without antibiotic exposure showed that antibiotic use amplified this Crohn's-associated dysbiosis. Comparisons across ileal, rectal, and fecal samples showed distinct microbial signatures by sample site at this early stage of disease.
What are the greatest implications of this study?
Because dysbiosis is detectable before treatment begins, the rectal mucosal-associated microbiome may offer a convenient, minimally invasive target for early diagnosis of Crohn's disease. The finding that antibiotics amplify dysbiosis suggests antibiotic exposure should be accounted for when interpreting microbiome studies in IBD. Identifying a consistent dysbiosis axis across a large pediatric cohort also helps reconcile inconsistencies seen among smaller prior studies.